SummitTX Capital’s Niagen Bioscience NAGE Stock Holding History

SummitTX Capital’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,361	Closed	-$78.6K	–	1017
2025 Q4	$78.6K	Buy	+12,361	New	+$86K	﹤0.01%	665

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SummitTX Capital's NAGE Position: Q1 2026 in Review

SummitTX Capital sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 12,361 shares — an estimated $78.6K sold.

SummitTX Capital first reported a position in NAGE in Q4 2025 and held it in 1 quarter. The position peaked at $78.6K in Q4 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

SummitTX Capital reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 12,361 Niagen Bioscience shares in Q1 2026, an estimated $78.6K.
SummitTX Capital first reported a position in Niagen Bioscience in Q4 2025 and held it in 1 quarter.
SummitTX Capital's Niagen Bioscience position peaked at $78.6K in Q4 2025.
143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.